title: Results of complete lymph node dissection in 83 melanoma patients with positive sentinel nodes.
abstract: BACKGROUND
  The technique of sentinel lymph node (SLN) biopsy for melanoma provides accurate staging information because the histology of the SLN reflects the histology of the entire basin, particularly when the SLN is negative.
  
  
  METHODS
  We combined two mapping techniques, one using vital blue dye and the other using radiolymphoscintigraphy with a hand-held gamma Neoprobe, to identify the SLN in 600 consecutive patients with stage I-II melanoma. The SLNs were examined using conventional histopathology and immunohistochemistry for S-100.
  
  
  RESULTS
  Eighty-three (13.9%) patients had micrometastatic disease in the SLNs. Thirty percent of patients with primary melanomas greater than 4.0 mm in thickness had positive SLNs, followed by 48 of 267 (18%) of patients with tumors between 1.5 mm and 4 mm, and 12 of 169 (7%) of those with lesions between 1.0 mm and 1.5 mm. No patient with a tumor less than 0.76 mm in thickness had a positive SLN. Sixty-four of the 83 SLN-positive patients consented to undergo complete lymph node dissection (CLND), and five of 64 (7.8%) of the CLNDs were positive. All patients with positive CLNDs had tumor thicknesses greater than 3.0 mm.
  
  
  CONCLUSIONS
  The rate of SLN-positive patients increases with increasing thickness of the melanoma. SLN-positive patients with primary lesions less than 1.5 mm in thickness may have disease confined to the SLN, thus rendering higher-level nodes free of disease, and may not require a CLND.
authors.affiliation: The Cutaneous Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa 33612-9497, USA.
authors.forename: E
authors.initials: E
authors.lastname: Joseph
authors.forename: A
authors.initials: A
authors.lastname: Brobeil
authors.forename: F
authors.initials: F
authors.lastname: Glass
authors.forename: J
authors.initials: J
authors.lastname: Glass
authors.forename: J
authors.initials: J
authors.lastname: Messina
authors.forename: R
authors.initials: R
authors.lastname: DeConti
authors.forename: C W
authors.initials: CW
authors.lastname: Cruse
authors.forename: D P
authors.initials: DP
authors.lastname: Rapaport
authors.forename: C
authors.initials: C
authors.lastname: Berman
authors.forename: N
authors.initials: N
authors.lastname: Fenske
authors.forename: D S
authors.initials: DS
authors.lastname: Reintgen
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001706:Biopsy; D002648:Child; D005121:Extremities / Q000000981:diagnostic imaging / Q000473:pathology / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D015902:Gamma Cameras; D006258:Head and Neck Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology / Q000601:surgery; D006801:Humans; D007150:Immunohistochemistry; D008197:Lymph Node Excision; D008198:Lymph Nodes / Q000000981:diagnostic imaging / Q000473:pathology*; D008207:Lymphatic Metastasis / Q000000981:diagnostic imaging / Q000473:pathology; D008297:Male; D008545:Melanoma / Q000000981:diagnostic imaging / Q000473:pathology / Q000556:secondary / Q000601:surgery*; D008875:Middle Aged; D009367:Neoplasm Staging; D011446:Prospective Studies; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D012394:Rosaniline Dyes; D009418:S100 Proteins / Q000032:analysis; D012878:Skin Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology / Q000601:surgery*; D013671:Technetium Tc 99m Sulfur Colloid; D013899:Thoracic Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology / Q000601:surgery
chemical_list: D019275:Radiopharmaceuticals; D012394:Rosaniline Dyes; D009418:S100 Proteins; C025484:iso-sulfan blue; D013671:Technetium Tc 99m Sulfur Colloid